Performance and safety of a moisturising hyaluronic acid-based ovule in alleviating vaginal dryness and dyspareunia: a prospective multicentre study.
Gynecol EndocrinolAug 26, 2026 (epub)
Clinical ResearchObstetrics & Gynecology
Ramez Ghadri, Raïssa Aperano-Mas, Christian Jean et al.
✦ AI-curated · Sources linked
In 30 seconds
This prospective multicentre clinical trial evaluated the efficacy and safety of MucoGYNE, a hyaluronic acid-based vaginal ovule, in women aged 18 and older with vaginal dryness. The study found a significant increase in Vaginal Health Index (VHI) scores, with a mean change of +6.1 ± 3.1 (p < 0.0001) after 5 weeks of treatment, indicating improved symptoms of vaginal dryness and dyspareunia.
Key findings
- VHI scores increased significantly with a mean change of +6.1 ± 3.1 (p < 0.0001).
- 89.7% of investigators reported clinical improvement in participants.
- 79.3% of participants perceived an improvement in their symptoms.
- 86.2% of women expressed satisfaction with the treatment.
Why it matters
Vulvovaginal dryness is a common issue affecting women's quality of life, particularly post-menopause. Effective non-hormonal treatments like MucoGYNE may provide relief and improve sexual function, addressing a significant gap in care.